Your browser doesn't support javascript.
loading
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi, Myrto K; Molero, Magdalena; Martinez Morilla, Sandra; Baena, Javier; Vathiotis, Ioannis A; Gavrielatou, Niki; Castro-Labrador, Laura; de Garibay, Gorka Ruiz; Adradas, Vera; Orive, Daniel; Valencia, Karmele; Calvo, Alfonso; Montuenga, Luis M; Ponce Aix, S; Schalper, Kurt A; Herbst, Roy S; Paz-Ares, Luis; Rimm, David L; Zugazagoitia, Jon.
Afiliación
  • Moutafi MK; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Molero M; Tumor Microenvironment and Immunotherapy Research Group, 12 de Octubre Research Institute (i+12), Madrid, Spain.
  • Martinez Morilla S; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Baena J; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Vathiotis IA; Tumor Microenvironment and Immunotherapy Research Group, 12 de Octubre Research Institute (i+12), Madrid, Spain.
  • Gavrielatou N; Department of Medical Oncology, 12 de Octubre Hospital, Madrid, Spain.
  • Castro-Labrador L; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • de Garibay GR; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Adradas V; Tumor Microenvironment and Immunotherapy Research Group, 12 de Octubre Research Institute (i+12), Madrid, Spain.
  • Orive D; Tumor Microenvironment and Immunotherapy Research Group, 12 de Octubre Research Institute (i+12), Madrid, Spain.
  • Valencia K; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Calvo A; Tumor Microenvironment and Immunotherapy Research Group, 12 de Octubre Research Institute (i+12), Madrid, Spain.
  • Montuenga LM; Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
  • Ponce Aix S; Department of Pathology, University of Navarra, Pamplona, Spain.
  • Schalper KA; Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
  • Herbst RS; Spanish Center for Biomedical Research Network in Oncology, CIBERONC, Madrid, Spain.
  • Paz-Ares L; Health Research Institute of Navarra, IdiSNA, Pamplona, Spain.
  • Rimm DL; Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
  • Zugazagoitia J; Department of Pathology, University of Navarra, Pamplona, Spain.
J Immunother Cancer ; 10(8)2022 08.
Article en En | MEDLINE | ID: mdl-36002182
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos